

Izidore S Lossos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6867827/publications.pdf>

Version: 2024-02-01

165
papers

13,033
citations

136950

32
h-index

23533

111
g-index

167
all docs

167
docs citations

167
times ranked

12792
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. <i>Nature</i> , 2000, 403, 503-511.	27.8	8,977
2	Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. <i>Nature Genetics</i> , 2014, 46, 166-170.	21.4	534
3	Extranodal marginal zone lymphoma of the ocular adnexa. <i>Blood</i> , 2009, 114, 501-510.	1.4	201
4	Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with <i>Chlamydia psittaci</i> . <i>Blood</i> , 2006, 107, 467-472.	1.4	197
5	The Genetic Basis of Hepatosplenic T-cell Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 369-379.	9.4	163
6	LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab. <i>Journal of Clinical Oncology</i> , 2008, 26, 447-454.	1.6	159
7	Transformation of follicular lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 147-163.	1.7	142
8	Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 6351-6357.	1.6	135
9	Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. <i>Blood</i> , 2005, 105, 3979-3986.	1.4	111
10	A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2020, 136, 2401-2409.	1.4	92
11	A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. <i>British Journal of Haematology</i> , 2014, 165, 358-363.	2.5	91
12	HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2003, 101, 433-440.	1.4	84
13	miR-155 regulates HGAL expression and increases lymphoma cell motility. <i>Blood</i> , 2012, 119, 513-520.	1.4	74
14	Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. <i>Nature Communications</i> , 2014, 5, 3904.	12.8	73
15	Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort. <i>American Journal of Hematology</i> , 2015, 90, 778-783.	4.1	71
16	MiR-181 family-specific behavior in different cancers: a meta-analysis view. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 17-32.	5.9	63
17	Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. <i>Blood Advances</i> , 2017, 1, 2600-2609.	5.2	62
18	Long-term course of patients with primary ocular adnexal MALT lymphoma: a large single-institution cohort study. <i>Blood</i> , 2017, 129, 324-332.	1.4	60

#	ARTICLE	IF	CITATIONS
19	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021, 137, 374-386.	1.4	59
20	Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. <i>Seminars in Cancer Biology</i> , 2003, 13, 191-202.	9.6	58
21	Urelumab alone or in combination with rituximab in patients with relapsed or refractory Bâ€cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 510-520.	4.1	56
22	GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo. <i>Blood</i> , 2016, 127, 2723-2731.	1.4	52
23	LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL. <i>Cancer Cell</i> , 2019, 36, 237-249.e6.	16.8	50
24	PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. <i>Blood</i> , 2018, 132, 2026-2039.	1.4	48
25	Apoptosis Stimulating Protein of p53 (ASPP2) Expression Differs in Diffuse Large B-cell and Follicular Center Lymphoma: Correlation with Clinical Outcome. <i>Leukemia and Lymphoma</i> , 2002, 43, 2309-2317.	1.3	47
26	Expression of the human germinal centerâ€associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival. <i>Blood</i> , 2007, 109, 298-305.	1.4	45
27	Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution. <i>Journal of Clinical Oncology</i> , 2018, 36, 3370-3380.	1.6	44
28	Pulmonary marginal zone lymphoma: A single centre experience and review of the SEER database. <i>Leukemia and Lymphoma</i> , 2008, 49, 1311-1320.	1.3	43
29	Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). <i>Journal of Hematology and Oncology</i> , 2017, 10, 171.	17.0	41
30	PRMT5-mediated histone arginine methylation antagonizes transcriptional repression by polycomb complex PRC2. <i>Nucleic Acids Research</i> , 2020, 48, 2956-2968.	14.5	38
31	Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation. <i>Nature Communications</i> , 2013, 4, 1338.	12.8	37
32	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021, 39, 1129-1138.	1.6	37
33	HGAL, a lymphoma prognostic biomarker, interacts with the cytoskeleton and mediates the effects of IL-6 on cell migration. <i>Blood</i> , 2007, 110, 4268-4277.	1.4	35
34	Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences. <i>Leukemia and Lymphoma</i> , 2017, 58, 882-888.	1.3	34
35	Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1630-1632.	1.3	32
36	Lmo2 expression defines tumor cell identity during Tâ€cell leukemogenesis. <i>EMBO Journal</i> , 2018, 37, .	7.8	32

#	ARTICLE	IF	CITATIONS
37	Treatment of isolated primary intraocular lymphoma with high-dose methotrexate-based chemotherapy and binocular radiation therapy: a single-institution experience. <i>British Journal of Haematology</i> , 2010, 151, 103-106.	2.5	31
38	Molecular and genomic aberrations in <i>Chlamydophila psittaci</i> negative ocular adnexal marginal zone lymphomas. <i>American Journal of Hematology</i> , 2013, 88, 730-735.	4.1	31
39	Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma. <i>Blood</i> , 2015, 126, 1555-1564.	1.4	31
40	HGAL, a germinal center specific protein, decreases lymphoma cell motility by modulation of the RhoA signaling pathway. <i>Blood</i> , 2010, 116, 5217-5227.	1.4	28
41	Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 524-535.	2.5	27
42	LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome. <i>Haematologica</i> , 2011, 96, 980-986.	3.5	26
43	Phase II study of ⁹⁰ Y ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1750-1755.	1.3	26
44	Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation. <i>American Journal of Hematology</i> , 2019, 94, 585-596.	4.1	25
45	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021, 5, 2852-2862.	5.2	24
46	Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. <i>Lancet Haematology</i> , 2022, 9, e289-e300.	4.6	24
47	Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2011, 118, 95-95.	1.4	23
48	Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 455-460.	4.1	22
49	Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis. <i>British Journal of Haematology</i> , 2008, 141, 69-72.	2.5	21
50	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021, 106, 1932-1942.	3.5	21
51	Interleukin 21 – its potential role in the therapy of B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2017, 58, 17-29.	1.3	20
52	Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study. <i>Blood</i> , 2019, 134, 2874-2874.	1.4	19
53	A roadmap for discovery and translation in lymphoma. <i>Blood</i> , 2015, 125, 2175-2177.	1.4	18
54	Rapid complete response to blinatumomab as a successful bridge to allogeneic stem cell transplantation in a case of refractory Richter syndrome. <i>Leukemia and Lymphoma</i> , 2019, 60, 230-233.	1.3	18

#	ARTICLE	IF	CITATIONS
55	Acute lymphoblastic leukemia mortality in Hispanic Americans. <i>Leukemia and Lymphoma</i> , 2020, 61, 2674-2681.	1.3	18
56	HGAL localization to cell membrane regulates B-cell receptor signaling. <i>Blood</i> , 2015, 125, 649-657.	1.4	17
57	Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 128, 239-248.	1.4	17
58	Human germinal center-associated lymphoma protein expression is associated with improved failure-free survival in Brazilian patients with classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1830-1836.	1.3	16
59	High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 406-414.	1.3	16
60	Germinal center-specific protein human germinal center associated lymphoma directly interacts with both myosin and actin and increases the binding of myosin to actin. <i>FEBS Journal</i> , 2011, 278, 1922-1931.	4.7	16
61	Active IKK β promotes the stability of GLI1 oncogene in diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 127, 605-615.	1.4	16
62	The Endless Complexity of Lymphocyte Differentiation and Lymphomagenesis: IRF-4 Downregulates BCL6 Expression. <i>Cancer Cell</i> , 2007, 12, 189-191.	16.8	15
63	Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and/or 13q14. <i>Annals of Diagnostic Pathology</i> , 2014, 18, 214-219.	1.3	15
64	Differentiation-Stage-Specific Expression of MicroRNAs in B-Lymphocytes and Diffuse Large B-Cell Lymphomas (DLBCL). <i>Blood</i> , 2008, 112, 805-805.	1.4	15
65	Diffuse Large B Cell Lymphoma: From Gene Expression Profiling to Prediction of Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 108-111.	2.0	14
66	Splenic marginal zone lymphoma: A US population-based survival analysis (1999-2016). <i>Cancer</i> , 2020, 126, 4706-4716.	4.1	14
67	Survival analysis in treated plasmablastic lymphoma patients: a population-based study. <i>American Journal of Hematology</i> , 2020, 95, 1344-1351.	4.1	14
68	Progressive multifocal leukoencephalopathy following treatment with bendamustine and rituximab. <i>International Journal of Hematology</i> , 2012, 96, 274-278.	1.6	13
69	Gastrointestinal Tract Lymphomas: A Review of the Most Commonly Encountered Lymphomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1585-1596.	2.5	13
70	Diffuse Large B-Cell Lymphoma: Insights Gained from Gene Expression Profiling. <i>International Journal of Hematology</i> , 2003, 77, 321-329.	1.6	12
71	A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1299-1305.	1.3	12
72	A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data. <i>Blood</i> , 2018, 132, 1620-1620.	1.4	12

#	ARTICLE	IF	CITATIONS
73	An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. <i>Blood Advances</i> , 2022, 6, 2035-2044.	5.2	12
74	Association between non-Hodgkin lymphoma and renal cell carcinoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 2254-2261.	1.3	11
75	Smoothed stabilizes and protects TRAF6 from degradation: A novel non-canonical role of smoothed with implications in lymphoma biology. <i>Cancer Letters</i> , 2018, 436, 149-158.	7.2	10
76	Recent BCR stimulation induces a negative autoregulatory loop via FBXO10 mediated degradation of HGAL. <i>Leukemia</i> , 2020, 34, 553-566.	7.2	10
77	Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial. <i>Blood Cancer Journal</i> , 2021, 11, 147.	6.2	10
78	Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis. <i>Blood</i> , 2019, 134, 402-402.	1.4	9
79	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2019, 134, 69-69.	1.4	9
80	Diagnostic bone marrow biopsy in patients with stage I EMZL treated with radiation therapy: needed or not?. <i>Blood</i> , 2020, 135, 1299-1302.	1.4	8
81	Treatments and Outcomes in Stage I Extranodal Marginal Zone Lymphoma in the United States. <i>Cancers</i> , 2021, 13, 1803.	3.7	8
82	Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 43-53.	1.3	8
83	Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival. <i>Blood</i> , 2018, 132, 4146-4146.	1.4	8
84	KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2017, 148, 465-476.	0.7	7
85	Interplay between HGAL and Grb2 proteins regulates B-cell receptor signaling. <i>Blood Advances</i> , 2019, 3, 2286-2297.	5.2	7
86	The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways. <i>Cancer Research Communications</i> , 2021, 1, 1-16.	1.7	7
87	Updated survival analysis of two sequential prospective trials of R ² MACLO ² VAM followed by maintenance for newly diagnosed mantle cell lymphoma. <i>American Journal of Hematology</i> , 2015, 90, E111-6.	4.1	6
88	Clinical and radiological characteristics of patients with pulmonary marginal zone lymphoma: A single center analysis. <i>Cancer Medicine</i> , 2020, 9, 5051-5064.	2.8	6
89	Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice. <i>Blood</i> , 2021, 137, 1741-1753.	1.4	6
90	The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States. <i>Blood</i> , 2018, 132, 1702-1702.	1.4	6

#	ARTICLE	IF	CITATIONS
91	BLIMP1 against Lymphoma: The Verdict Is Reached. <i>Cancer Cell</i> , 2010, 18, 537-539.	16.8	5
92	CD4+/CD8+ immunophenotype switching as a marker for intraocular and CNS involvement in mycosis fungoides. <i>Leukemia and Lymphoma</i> , 2019, 60, 1308-1311.	1.3	5
93	Stage I DLBCL: extranodal may mean extra radiation. <i>Blood</i> , 2021, 137, 3-5.	1.4	5
94	Genetic Analysis of Plasmablastic Lymphomas in HIV (+) Patients Reveals Novel Driver Regulators of the Noncanonical NF- κ B Pathway. <i>Blood</i> , 2018, 132, 1565-1565.	1.4	5
95	Long-term outcomes of frontline 90Y-ibritumomab tiuxetan in marginal zone lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 3234-3238.	1.3	4
96	Atezolizumab in Combination with Obinutuzumab and Lenalidomide Demonstrates Favorable Activity and Manageable Toxicity in Patients with Relapsed/Refractory Follicular Lymphoma (FL): An Interim Analysis of a Phase Ib/II Trial. <i>Blood</i> , 2018, 132, 1603-1603.	1.4	4
97	Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis. <i>Blood</i> , 2020, 136, 2-3.	1.4	4
98	IL-4 Affects Proliferation, Chemosensitivity and Rituximab Sensitivity of Germinal Center B-Cell like (GCB) and Activated B-Cell like (ABC) Diffuse Large B-Cell Lymphoma Differently.. <i>Blood</i> , 2004, 104, 242-242.	1.4	4
99	LMO2 expression is frequent in T-lymphoblastic leukemia and correlates with survival, regardless of T-cell stage. <i>Modern Pathology</i> , 2022, 35, 1220-1226.	5.5	4
100	Non-Hodgkin's Lymphoma in the Microarray Era. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 128-129.	2.1	3
101	DA-EPOCH-R for Adult Burkitt's Lymphoma: Pros and Cons. <i>Journal of Oncology Practice</i> , 2018, 14, 676-678.	2.5	3
102	Primary thyroid lymphoma: survival analysis of SEER database (1995-2016). <i>Leukemia and Lymphoma</i> , 2021, 62, 2796-2799.	1.3	3
103	The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC). <i>Blood</i> , 2019, 134, 397-397.	1.4	3
104	Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database. <i>Blood</i> , 2019, 134, 1610-1610.	1.4	3
105	Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 46-47.	1.4	3
106	Targeting B-Cell Malignancies With Anti-CD20-Interleukin-21 Fusokine. <i>Blood</i> , 2013, 122, 377-377.	1.4	3
107	A Prospective Multicenter Study of Minimal Residual Disease Assessment Using a Next-Generation Immunosequencing Assay and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 52-52.	1.4	3
108	Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. <i>Blood Advances</i> , 2022, 6, 2745-2756.	5.2	3

#	ARTICLE	IF	CITATIONS
109	Long-term outcomes of patients with conjunctival extranodal marginal zone lymphoma. American Journal of Hematology, 2023, 98, 148-158.	4.1	3
110	Splenic B-Cell Lymphomas with Diffuse Cyclin D1 Protein Expression and Increased Polymphocytic Cells: A Previously Unrecognized Diagnostic Pitfall. Case Reports in Hematology, 2018, 2018, 1-9.	0.4	2
111	NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma—opportunities for therapy. Leukemia and Lymphoma, 2022, 63, 279-290.	1.3	2
112	HGAL inhibits lymphoma dissemination by interacting with multiple Cytoskeletal proteins. Blood Advances, 2021, 5, 5072-5085.	5.2	2
113	High Remission Rates and Prolonged Progression Free Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma Treated with R-MACLOIVAM-T. Blood, 2008, 112, 3597-3597.	1.4	2
114	Interleukin-21 Induces Cell Cycle Arrest and Apoptosis of Diffuse Large B-Cell Lymphomas (DLBCL) Via Activation of STAT3 and Upregulation of C-Myc. Blood, 2008, 112, 601-601.	1.4	2
115	Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity. Blood, 2012, 120, 1618-1618.	1.4	2
116	Novel Use of Endoscopic Clips as Fiducials for Radiotherapy in Small Bowel Lymphoma. ACG Case Reports Journal, 2014, 1, 184-186.	0.4	2
117	A single-center analysis of patients with extranodal marginal zone lymphoma of the breast. Leukemia and Lymphoma, 2022, 63, 591-598.	1.3	2
118	Immunoglobulin Light Chain Use and Characteristics in the Chlamydochloa Psittaci negative MALT Lymphomas of the Ocular Adnexa. Blood, 2012, 120, 1597-1597.	1.4	2
119	Human Germinal Center-associated Lymphoma (HGAL) Is a Reliable Marker of Normal and Neoplastic Follicular Helper T Cells Including Angioimmunoblastic T-Cell Lymphoma. American Journal of Surgical Pathology, 2021, Publish Ahead of Print, .	3.7	2
120	Marginal zone lymphoma of the colon: case series from a single center and SEER data review. Leukemia and Lymphoma, 2022, 63, 1160-1166.	1.3	2
121	IL-4 in lymphoma: Does the target matter?. Leukemia and Lymphoma, 2007, 48, 1261-1263.	1.3	1
122	Hepatosplenic T-cell lymphoma associated with membranoproliferative glomerulonephritis. Leukemia and Lymphoma, 2017, 58, 2734-2737.	1.3	1
123	R-MACLOIVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma—Long term follow up results. American Journal of Hematology, 2021, 96, 680-689.	4.1	1
124	Mantle cell lymphoma involving the thyroid gland. Clinical Case Reports (discontinued), 2021, 9, e04104.	0.5	1
125	Omission of Staging Bone Marrow Biopsy Does Not Affect Outcomes in Patients with Stage I Extranodal Marginal Zone Lymphoma (EMZL) Treated with Radiation Therapy. Blood, 2019, 134, 2829-2829.	1.4	1
126	R-MACLO-IVAM Is an Effective Regimen to Induce Long Term Remission in Untreated Mantle Cell Lymphoma. Blood, 2019, 134, 3992-3992.	1.4	1

#	ARTICLE	IF	CITATIONS
127	High Incidence of False Positive PET Scans in Patients with Aggressive Non-Hodgkins Lymphoma Treated with Rituximab-Containing Regimens.. Blood, 2006, 108, 2401-2401.	1.4	1
128	Phase-2 Study of R-MACLO-IVAM-T in Newly Diagnosed Mantle Cell Lymphoma.. Blood, 2007, 110, 1363-1363.	1.4	1
129	Paraffin-Based 6-Gene Model Predicts Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.. Blood, 2007, 110, 49-49.	1.4	1
130	miR155 DOWNREGULATES EXPRESION of HGAL and INCREASES LYMPHOMA CELL MOTILITY. Blood, 2010, 116, 464-464.	1.4	1
131	Recurrent Rhoa Mutations In Peripheral T-Cell Lymphoma. Blood, 2013, 122, 846-846.	1.4	1
132	Motexafin Gadolinium (MGd) Has Clinical Activity in Relapsed/Refractory Low Grade Lymphomas (LG) and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).. Blood, 2005, 106, 4758-4758.	1.4	1
133	PTPN2, Distinctively Expressed in GCB-Like and ABC-Like DLBCL, Is the Nuclear Phosphatase of STAT6.. Blood, 2005, 106, 418-418.	1.4	1
134	A Phase II Trial of Combination Bortezomib (Velcade®) and Rituximab for Untreated High Tumor Burden Indolent Non-Hodgkin Lymphoma (NHL).. Blood, 2008, 112, 2004-2004.	1.4	1
135	Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL). Blood, 2019, 134, 4010-4010.	1.4	1
136	Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. Blood, 2020, 136, 49-50.	1.4	1
137	Characteristics and outcomes of lymphoblastic lymphoma “ the University of Miami experience. Leukemia and Lymphoma, 2017, 58, 195-198.	1.3	0
138	Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy. Leukemia and Lymphoma, 2018, 59, 2096-2104.	1.3	0
139	Intracytoplasmic azurophilic inclusions in polymorphocytes. International Journal of Hematology, 2018, 108, 565-565.	1.6	0
140	Central nervous system emergencies in haematological malignancies. British Journal of Haematology, 2020, 189, 1028-1037.	2.5	0
141	Expression of the Human Germinal Center Associated Lymphoma (HGAL) Protein Identifies a Subset of Classical Hodgkin Lymphoma of Germinal Center Derivation and Improved Outcome.. Blood, 2005, 106, 23-23.	1.4	0
142	RNA-Binding Protein VICKZ Is Expressed in a Germinal Center Associated Pattern among Lymphoma Subtypes.. Blood, 2005, 106, 1909-1909.	1.4	0
143	PTP1B, Distinctively Expressed in GCB-Like and ABC-Like DLBCL, Is a New Regulator of IL-4-STAT6 Intracellular Signaling.. Blood, 2007, 110, 1558-1558.	1.4	0
144	Primary Non-Hodgkin™s Lymphoma of the Lung.. Blood, 2007, 110, 4402-4402.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Lack of Survival Improvement in Patients with Large Cell Lymphomas of T-Cell Phenotype: A SEER Analysis Comparing Outcomes According to Phenotype and Year of Diagnosis.. Blood, 2007, 110, 3577-3577.	1.4	0
146	The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms with rare exceptions. FASEB Journal, 2008, 22, 902.15.	0.5	0
147	Darinaparsin a Novel Organic Arsenic Molecule Active in Lymphoma: Development of An Oral Form.. Blood, 2009, 114, 4759-4759.	1.4	0
148	Dissecting the Genetic Basis of Marginal Zone Lymphoma Reveals a Predisposition for NF-Kb Activation by Clonal MZL Located at Extranodal Sites. Blood, 2010, 116, 4160-4160.	1.4	0
149	Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment. Blood, 2010, 116, 2006-2006.	1.4	0
150	STAT3, Constitutively Activated In ABC-Like DLBCL, Regulates Expression of the Prognostic Factor Cyclin D2. Blood, 2010, 116, 705-705.	1.4	0
151	MiR-181a Is a Master Regulator of the Nuclear Factor- κ B Signaling Pathway in Diffuse Large B Cell Lymphoma. Blood, 2012, 120, 417-417.	1.4	0
152	B Cell Receptors Of Chlamydophila Psittaci negative MALT Lymphomas Of The Ocular Adnexa Recognize Common Self-Antigens. Blood, 2013, 122, 4266-4266.	1.4	0
153	Germinal Center Kinase Regulates The Proliferation and Survival Of Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 643-643.	1.4	0
154	Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumor burden (HTB) indolent non-Hodgkin lymphoma (iNHL): A multicenter phase II study.. Journal of Clinical Oncology, 2014, 32, 8545-8545.	1.6	0
155	Mirna-181a expression Lead to Longer Animal Survival and Slower Tumor-Growth Rate in Diffuse Large B-Cell Lymphoma Xenograft Models. Blood, 2014, 124, 2963-2963.	1.4	0
156	Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome. Blood, 2014, 124, 1703-1703.	1.4	0
157	Integrative Genomics Reveals a Role for GNA13 in Lymphomagenesis within the Germinal Center Niche. Blood, 2014, 124, 782-782.	1.4	0
158	Characteristics and Outcomes of Lymphoblastic Lymphoma Patients - the University of Miami Experience. Blood, 2015, 126, 5083-5083.	1.4	0
159	FBXO10 Targets HGAL for Degradation. Blood, 2015, 126, 3904-3904.	1.4	0
160	Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): Pathologic Classification and Clinical Outcomes from a Multicenter Consensus Study. Blood, 2016, 128, 4145-4145.	1.4	0
161	Indolent Lymphoma and Vitamin D (iLyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival in Patients with Low Tumor Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab. Blood, 2019, 134, 4008-4008.	1.4	0
162	Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis. Blood, 2021, 138, 338-338.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma. Blood, 2020, 136, 15-16.	1.4	0
164	Prognostic Value of PET/CT Metrics in Patients with Relapsed and Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Platinum-Based Chemotherapy: An Intent-to-Treat Analysis. Blood, 2020, 136, 14-15.	1.4	0
165	The Burkitt Lymphoma International Prognostic Index (BL-IPI). Blood, 2020, 136, 46-49.	1.4	0